Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

Plain-language guide to NCT07179120: phase 2 randomized trial of Tirzepatide and Semaglutide, fat loss, obesity & body recomposition, 180 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07179120
Phase: phase 2
Status: not yet recruiting
Start: 2026-05-01
Completion (planned or actual): 2026-08-12
Participants: 180 (estimated)
Design: randomized, single-blind, treatment
Conditions studied: Obesity-related Male Infertility
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

The trial (phase 2) is built around Tirzepatide and Semaglutide for fat loss, obesity & body recomposition and male fertility and sperm.

Why is this study being done?

Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children.

Weight loss through diet and exercise helps, but it's often hard to stick with.

It had three arms (groups): Semaglutide Injection Therapy (Intervention A Group) (experimental), Tirzepatide Injection Therapy (Intervention B Group) (experimental) and Lifestyle Modification Management (Control Group) (experimental).

The registry classes the interventions as behavioral and drug.

Who Took Part

Enrollment: 180 planned participants were the target.

It was open to men only aged from 20 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 1 inclusion and 1 exclusion criteria.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

The fat loss, obesity & body recomposition participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The Tirzepatide group and the comparison group ran side by side rather than switching.

In this single-blind Tirzepatide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-05-01 with completion listed for 2026-08-12.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention (time frame: Baseline and Week 32).

It also tracked 9 secondary outcomes, for example Change from Baseline in Total Sperm Count at Week 32, Change from Baseline in Sperm Motility (Progressive + Non-progressive) at Week 32, Change from Baseline in Serum Total Testosterone Level at Week 32, Change from Baseline in Follicle-Stimulating Hormone (FSH) Level at Week 32, Change from Baseline in Luteinizing Hormone (LH) Level at Week 32 and Change from Baseline in Body Mass Index (BMI) at Week 32.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide and Semaglutide in 180 people with fat loss, obesity & body recomposition.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Semaglutide compound page, Fat loss, obesity & body recomposition research, Male fertility and sperm research.

Our Notes on the Compounds

Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.